Tenax Therapeutics (TENX) announced the appointment of Gillian Andor, MSc, as Vice President, Clinical Operations. Andor will lead the Company’s expanding Clinical Operations function in support of the ongoing Phase 3 program evaluating oral levosimendan for the treatment of pulmonary hypertension due to heart failure with preserved ejection fraction. She served most recently as Interim Head, Clinical Development Operations with Noema Pharma.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TENX: